Urinary Retention Drug Market Report 2026

The urinary retention drug market size has grown strongly in recent years. It will grow from $4.07 billion in 2025 to $4.31 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to aging male population, increasing BPH prevalence, hospital surgical volume growth, neurogenic disorder diagnosis, catheterization limitations.

The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to homecare drug adoption, minimally invasive therapy growth, chronic urinary disorder management, outpatient urology expansion, improved drug adherence. Major trends in the forecast period include rising use of alpha blockers for BPH, growth of neurogenic bladder treatments, expansion of oral retention therapies, increased focus on postoperative care, shift toward long-term bladder management.

The growing incidence of urinary disorders is anticipated to drive expansion in the urinary retention drug market. Urinary disorders encompass conditions impacting the urinary system, resulting in problems like challenges with urination, discomfort, incontinence, or retention. This uptick stems from higher rates of diabetes, where elevated blood sugar harms the kidneys and urinary tract, contributing to issues such as diabetic nephropathy and recurrent urinary tract infections. Urinary retention drugs address these disorders by enhancing urine flow, easing bladder muscle tension, and relieving symptoms like urination difficulties, which improves patient comfort and bladder performance. For instance, in October 2023, the National Health Service (NHS) England, a UK government body, reported that hospitals logged 147,285 admissions in 2022/23 primarily for urinary tract infections (UTIs). Patients over 65 represented 56% of these, or 82,392 cases, with the 80-84 age group seeing the peak at 17,280 admissions. Thus, the increasing prevalence of urinary disorders is fueling growth in the urinary retention drug market.

Leading firms in the urinary retention pharmaceuticals sector are prioritizing innovative delivery systems, like extended-release tablets, to boost patient adherence and deliver sustained symptom control. Extended-release (ER) tablets represent a formulation that slowly disperses the active pharmaceutical ingredient over time. This gradual release approach sustains steady drug levels in the blood, allowing less frequent administration than with immediate-release versions. For example, in April 2024, Zydus Lifesciences Limited, a pharmaceutical firm from India, introduced a generic form of Mirabegron for overactive bladder (OAB). Mirabegron works as a selective beta-3 adrenergic agonist to ease bladder muscle tension, alleviating urgency, frequency, and incontinence in urination. Though mainly indicated for OAB, it aids in addressing urinary retention linked to overactive bladder issues. The drug comes as a once-daily oral tablet.

In November 2024, Boston Scientific Corporation, a U.S.-based healthcare firm, purchased Axonics Inc. for $3.3 billion. Through this acquisition, Boston Scientific seeks to broaden its urology offerings by integrating cutting-edge technologies that tackle urinary and bowel dysfunction. Axonics Inc., a U.S.-based medical technology firm, focuses on sacral neuromodulation (SNM) therapy for urinary control, which treats urinary retention and overactive bladder symptoms.

Major companies operating in the urinary retention drug market are Astellas Pharma Inc., Ferring Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis International AG, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Cipla Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bayer AG.

North America was the largest region in the urinary retention drug market in 2025. The regions covered in the urinary retention drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary retention drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the urinary retention drug market by increasing the cost of imported APIs, intermediates, and excipients used in alpha blockers and anticholinergic formulations. These impacts have been most pronounced in branded therapies, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced formulation cost pressures. However, tariffs have promoted domestic generic drug manufacturing and localized production, supporting affordability.

The urinary retention drug market research report is one of a series of new reports that provides urinary retention drug market statistics, including urinary retention drug industry global market size, regional shares, competitors with a urinary retention drug market share, detailed urinary retention drug market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention drug industry. This urinary retention drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary retention medications help manage conditions involving trouble emptying the bladder, typically by easing bladder muscle tension or prompting contractions to facilitate urine release. Doctors prescribe them for issues like benign prostatic hyperplasia (BPH) or neurogenic bladder, which enhances bladder performance and eases associated discomfort.

The primary drug categories for treating urinary retention consist of alpha blockers, beta-3 agonists, anticholinergics, and surgical agents. Alpha blockers work by relaxing muscles in the bladder and prostate to enhance urine flow and ease symptoms of benign prostatic hyperplasia (BPH). These medications treat conditions like chronic urinary retention, postoperative urinary retention, and neurogenic bladder. They come in various forms, including oral, injectable, and transdermal, and serve diverse settings such as hospitals, home homecare, specialty clinics, and more.

The urinary retention drugs market consist of sales of tamsulosin (flomax), bethanechol (urecholine), terazosin (hytrin), doxazosin (cardura), finasteride (proscar), and alfuzosin (uroxatral). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.